1. Volume 15, Issue 1, Pages S20-S28 (January 2012)
Evidence to Inform Decision Makers in Thailand: A Cost-Effectiveness Analysis of Screening and Treatment Strategies for Postmenopausal Osteoporosis 
Pritaporn Kingkaew, BPharm, MSc, Usawadee Maleewong, BPharm, PhD, Chardpraorn Ngarmukos, MD, Yot Teerawattananon, MD, PhD 
Value in Health 
Volume 15, Issue 1, Pages S20-S28 (January 2012)
DOI: /j.jval
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1
Decision tree illustrating two systematic screening compare to ‘Null’ scenario, followed by Markov model representing a disease partway once postmenopausal women are diagnosed with osteoporosis.
Value in Health  , S20-S28DOI: ( /j.jval )
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
Incremental cost-effectiveness plane illustrating two selected age group, 50 years and 80 years.
Value in Health  , S20-S28DOI: ( /j.jval )
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

4. Fig. 3
Incremental cost-effectiveness ratios of providing different universal screening strategies at various age groups.
Value in Health  , S20-S28DOI: ( /j.jval )
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

5. Fig. 4
Cost-effectiveness acceptability curves of treatment options (A) in patients who start the treatments for primary prevention of osteoporotic fractures at the ages of 50 and 80 (B) in patients who start the treatments for secondary prevention of osteoporotic fractures at the ages of 50 and 80.
Value in Health  , S20-S28DOI: ( /j.jval )
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

6. Fig. 5
Cost-effectiveness acceptability curves of screening modalities for osteoporosis in postmenopausal women ages 50 and 80. If positive results confirm with DXA, alendronate will be given to osteoporosis patients for primary prevention of osteoporotic fractures.
Value in Health  , S20-S28DOI: ( /j.jval )
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

7. Fig. 6
One-way sensitivity analysis of adjusting drug compliance of all drugs and discontinuation of bisphosphonate (Primary prevention of osteoporotic fractures).
Value in Health  , S20-S28DOI: ( /j.jval )
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

8. Fig. 7
One-way sensitivity analysis of adjusting drug compliance of all drugs and discontinuation of bisphosphonate (Secondary prevention of osteoporotic fractures).
Value in Health  , S20-S28DOI: ( /j.jval )
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions